Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. More precise phenotyping of cluster headache using prospective attack reports

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Acute endovascular reperfusion treatment in patients with ischaemic stroke and large-vessel occlusion (Denmark 2011–2017)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Disturbed sleep in cluster headache is not the result of transient processes associated with the cluster period

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Disturbances of consciousness and sleep-wake functions in patients following brainstem lesions

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. European Academy of Neurology guideline on trigeminal neuralgia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND PURPOSE: To optimize subcutaneous therapy with immunoglobulins, large volume infusion of immunoglobulin G facilitated by pretreatment with hyaluronidase (fSCIG) was compared to conventional infusion of multiple small dosages (cSCIG) in 20 patients with multifocal motor neuropathy.

METHODS: A randomized, non-inferiority and observer-blinded cross-over design was applied with a treatment period of 24 weeks for each therapy.

RESULTS: In 18 patients fSCIG was feasible, two patients leaving the study due to side-effects. The primary study variable, isometric strength, was unchanged, being 100.8% [95% confidence interval (CI) 94.8%-107.1%) in fSCIG and 105.9% (95% CI 99.8%-112.0%) in cSCIG. Secondary end-points of disability, functions, impairments and quality of life showed no differences between the two treatments. Mild and short-lasting generalized side-effects were similar in the two groups, whereas the relative frequency of localized side-effects at the injection site was increased after fSCIG [0.63 (95% CI 0.23-1.00) vs. 0.09 (95% CI 0.00-0.22), P = 0.005]. The preference of the patients favoured fSCIG for two out of five visual analogue scale scores as well as the total mean score of all preferences (P = 0.03).

CONCLUSIONS: Facilitated SCIG seems effective, feasible and safe. In addition, it is preferred by patients but is accompanied by a higher frequency of short-lasting localized side-effects.

Original languageEnglish
JournalEuropean Journal of Neurology
Volume26
Issue number10
Pages (from-to)1289-e82
ISSN1351-5101
DOIs
Publication statusPublished - Oct 2019

    Research areas

  • clinical trials randomized controlled, immunoglobulin, multifocal motor neuropathy, peripheral neuropathy, treatment

ID: 58450856